Healthcare

EMvision reported surpassing pivotal-trial enrolment milestones while holding around A$17.1 million in cash, supporting its progress toward FDA clearance. The company has also secured milestone payments and additional funding — including a reported A$12 million raise — to advance its stroke-imaging programs. Its technology …

CLEO Diagnostics (ASX:COV) is moving its ovarian cancer blood test through a validation programme that will determine the next stage of its United States regulatory strategy. The pre-revenue diagnostics developer has completed commercial assay preparation, expanded testing capacity and collected samples for its pivotal …

The defining event was the FY26 result on 19 August 2026, covering the year to 30 June 2026. Healius reported underlyingRevenuefrom continuing operations of $1,373.2 million, up 2.1%, and a sharp lift in underlying EBIT to $30.2 million, up almost 77% from $17.1 million. …